FEV1 Percent Predicted Is a Marker of Lung Health in Pediatric Asthma
Burden Of Disease
Guidelines & recommendations
Type 2 inflammation
Learn how FEV1pp can be used to manage asthma in pediatric patients and understand future risks associated with reduced FEV1pp and pediatric disease severity.
MAT-US-2201151 V1 03/15/2024
Please rotate you device for optimal viewing
ADVENT is a medical education program by Sanofi and Regeneron. This website is intended only for health care professionals in the US only.
ADVENT is a global medical education program by Sanofi and Regeneron and is only intended for healthcare providers.
Sanofi Genzyme does not review or control the content of non–Sanofi Genzyme websites, and this hyperlink does not constitute an endorsement by Sanofi Genzyme of the site’s content. Sanofi Genzyme’s privacy procedures do not apply to the owners of a non–Sanofi Genzyme website.
Would you like to receive updates on new ADVENT content, courses and events when available?
MAT-US-2104233 Exp 04/26/2023
Congratulations, you are now subscribed successfully.
You will receive a confirmation email at the address you provided.
If you don’t receive it, please check your spam.